Ultime notizie per Compass Pathways (NASDAQ:CMPS) Azioni

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Compass Pathways: Phase 3 Trial Delay - Both Understandable And Disappointing

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target ...

BTIG Keeps Their Buy Rating on COMPASS Pathways (CMPS)

Massachusetts psychedelics legalization initiative poised to fail

In this edition of "Rising High," The Fly conducted an exclusive interview with Adam Wilks, Co-Founder and CEO of Carma HoldCo, a house of brands f...

Rising High: Exclusive talk with house of brands Carma HoldCo

Mind Medicine: No News = Good News

Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on CMPS stock, giving a Buy rating on November 4. Sumant Kulkarni's r...

Strategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price Target

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up

H.C. Wainwright lowered the firm's price target on Atai Life Sciences (ATAI) to $10 from $15 and keeps a Buy rating on the shares. The company repo...

Atai Life Sciences price target lowered to $10 from $15 at H.C. Wainwright

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on a clinic sale, effic...

Rising High: Numinus Wellness to sell five Utah clinics for $3.53M

AAWH

ATAI

AYRWF

BNTX

CANN

CBSTF

CMND

CMPS

CRLBF

CRON

CVSI

CYBN

DRUG

ENVB

GHRS

GRWG

GTBIF

IMCC

IXHL

MEDIF

MNMD

MRNA

NLCP

NVAX

PCVX

RLMD

RVVTF

SEEL

SHFS

TCNNF

TLRY

VREOF

VRNOF

News

Health Care

Press Releases

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Management

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways to announce second quarter financial results on August 1, 2024

Earnings

Compass Pathways announces second quarter 2024 financial results and business highlights

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways to participate in three investor conferences in September

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to participate in Stifel 2024 Healthcare Conference

COLL

Absci

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

C4 Therapeutics

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Precigen

Prime Medicine

Q32 Bio

AVITA Medical

Rezolute

Sage Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tevogen Bio Holdings

Valneva

Verve Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

HC Wainwright & Co.

Maxim Group

RBC Capital

Canaccord Genuity

Morgan Stanley

Comments

Compass Pathways

Notizie

Ultime notizie per Compass Pathways (NASDAQ:CMPS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO